Oncology

News

Histopathological image representing a bone marrow aspirate in a patient with essential thrombocythemia

MSD starts second phase 3 of Imago drug for blood cancers

MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (M

News

After FDA no, Regeneron gets yes from EU on odronextamab

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.

News

J&J's Balversa is first pan-FGFR bladder cancer drug in EU

Johnson & Johnson's Balversa has become the first drug approved in the EU to treat adults with advanced urothelial carcinoma (mUC) with FGFR3 genetic alterations after one line of prior

News

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou

Oncology

CDK9 inhibitors: Disrupting cancer cell growth and the treat...

We have made significant strides in cancer treatment in the last decade and a half.

News

EU starts review of Enhertu in HER2-ultra-low breast cancer

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER

MSD starts second phase 3 of Imago drug for blood cancers

After FDA no, Regeneron gets yes from EU on odronextamab

J&J's Balversa is first pan-FGFR bladder cancer drug in EU

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

CDK9 inhibitors: Disrupting cancer cell growth and the treat...

EU starts review of Enhertu in HER2-ultra-low breast cancer

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

Oncology

Editor's Picks